LEADS BIOLABS-B (09887) Income Statement & Earnings

74.600
+5.550+8.04%

15min DelayMarket Closed Aug 25 16:07 CST

14.84BMarket Cap-63.38P/E (TTM)

LEADS BIOLABS-B (09887) Income Statement

Cumulative·All

YOY

Hide blank lines

Currency: CNY

2025/FY

2025/H1

2025/Q1

2024/FY

2024/H1

2024/Q1

2023/FY

2023/H1

2022/FY

Total Revenue

--177.26M

----

--8.87M

----

Operating Revenue

--177.26M

----

--8.87M

----

Cost of Revenue

----

---3.19M

----

Cost of Goods Sold

----

---3.19M

----

Gross Profit

--177.26M

----

--5.68M

----

Operating Expense

-18.33%-371.24M

+9.07%-167.17M

+13.40%-76.26M

+17.44%-313.74M

+0.55%-183.84M

---88.06M

-30.95%-380.00M

---184.85M

---290.20M

Administrative Expenses

+5.69%-82.70M

+39.03%-35.83M

-36.01%-18.88M

-130.48%-87.69M

-234.14%-58.76M

---13.88M

-57.39%-38.05M

---17.59M

---24.17M

Research and Development Expenses

-55.69%-289.09M

-56.92%-131.81M

-33.46%-57.75M

+19.57%-185.68M

+26.98%-84.00M

---43.27M

-24.85%-230.86M

---115.04M

---184.91M

Revaluation Surplus

+101.34%541.00K

+101.14%470.00K

+101.19%368.00K

+63.67%-40.37M

+21.34%-41.08M

---30.91M

-36.97%-111.10M

---52.23M

---81.11M

-Changes in The Fair Value of Financial Assets

-68.51%541.00K

-53.28%470.00K

-15.21%368.00K

-73.31%1.72M

-75.81%1.01M

--434.00K

-71.58%6.44M

--4.16M

--22.65M

-Changes in The Fair Value of Other Assets

----

+64.19%-42.08M

+25.36%-42.08M

---31.35M

-13.27%-117.53M

---56.38M

---103.76M

Special Items of Operating Income

-71.11%5.28M

-24.50%4.41M

+24.99%2.80M

+35.76%18.29M

-39.82%5.84M

--2.24M

+38.82%13.47M

--9.70M

--9.71M

Operating Profit

+36.13%-188.71M

+8.56%-162.76M

+14.40%-73.46M

+18.12%-295.45M

-1.63%-178.00M

---85.83M

-28.65%-360.85M

---175.15M

---280.49M

Financing Cost

-24.71%-7.19M

-51.40%-3.63M

-155.91%-1.90M

-311.71%-5.76M

-405.05%-2.40M

---744.00K

-371.38%-1.40M

---475.00K

---297.00K

Pretax Profit

+34.97%-195.89M

+7.76%-166.39M

+12.94%-75.37M

+16.85%-301.22M

-2.72%-180.40M

---86.57M

-29.01%-362.25M

---175.62M

---280.79M

Tax

---15.53M

----

Net Profit

+29.81%-211.42M

+7.76%-166.39M

+12.94%-75.37M

+16.85%-301.22M

-2.72%-180.40M

---86.57M

-29.01%-362.25M

---175.62M

---280.79M

Profit from Continuing Operations

+29.81%-211.42M

+7.76%-166.39M

+12.94%-75.37M

+16.85%-301.22M

-2.72%-180.40M

---86.57M

-29.01%-362.25M

---175.62M

---280.79M

Net Income to Parent Company

+29.81%-211.42M

+7.76%-166.39M

+12.94%-75.37M

+16.85%-301.22M

-2.72%-180.40M

---86.57M

-29.01%-362.25M

---175.62M

---280.79M

Net Income to Common Stockholders

+29.81%-211.42M

+7.76%-166.39M

+12.94%-75.37M

+16.85%-301.22M

-2.72%-180.40M

---86.57M

-29.01%-362.25M

---175.62M

---280.79M

Basic EPS

+39.80%-1.21

+13.11%-1.06

+18.64%-0.48

+19.60%-2.01

+0.00%-1.22

---0.59

-28.21%-2.50

---1.22

---1.95

Diluted EPS

+39.80%-1.21

+13.11%-1.06

+18.64%-0.48

+19.60%-2.01

+0.00%-1.22

---0.59

-28.21%-2.50

---1.22

---1.95

Deadline

Dec 31, 2025

Jun 30, 2025

Mar 31, 2025

Dec 31, 2024

Jun 30, 2024

Mar 31, 2024

Dec 31, 2023

Jun 30, 2023

Dec 31, 2022

Accounting Standard

IAS

Audit Opinions

	2025/FY	2025/H1	2025/Q1	2024/FY	2024/H1	2024/Q1	2023/FY	2023/H1	2022/FY

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"